Biogen leans on newly acquired Apellis' Empaveli and Syfovre to offset Leqembi's disappointing Alzheimer's sales ahead of Q2 earnings.
It’s no secret that sales of Leqembi have been disappointing.
First approved in 2023, the Alzheimer’s drug from Eisai and Biogen launched shortly after Chris …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to…
The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows…
Eisai (ESAIY) and Biogen (BIIB) announced that new data presented at the Alzheimer’s Association International Conference, AAIC,…
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in…
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
